Elanco Bulls Lean In Ahead of Q2 Print

Elanco Animal Health heads into its August 5 earnings report with options traders leaning more bullish than usual and analysts steadily lifting targets — yet short sellers maintain a meaningful presence that keeps the setup from looking one-sided.

Options positioning reflects unusual confidence heading into the print. The put/call ratio has fallen to 0.38, below its 20-day average of 0.40, and the z-score of -0.73 confirms the tilt toward calls rather than downside protection. That's a modest but consistent signal: investors are paying more for upside exposure than they typically do in the weeks before an Elanco report. The stock has backed this up with a 5.9% gain on the week, extending a 7.2% one-month advance to close at $26.37.

The analyst community has been directionally constructive. Morgan Stanley's Erin Wright raised her target from $23 to $26 on July 22, though the Equal-Weight rating tells its own story — she sees the stock fairly valued near current levels, not a screaming buy. The broader consensus mean target sits at $30.07, implying about 14% upside from here, with multiple firms holding Buy-equivalent ratings backed by targets in the $30–$32 range. Bulls point to Simparica Trio's commanding 50%-plus market share in companion animal health and Credelio Quattro's rapid share gains as evidence of a durable product cycle. Bears counter that EBITDA margins have compressed even as revenues climbed, and that the company's refinancing burden — meaningful debt at rising rates — could continue to pressure near-term earnings conversion. Factor scores add a nuanced layer: EPS 12-month forward estimates rank in the 76th percentile, while actual EPS surprise history ranks in only the 12th, a gap that captures precisely the refinancing-related earnings drag bears keep flagging.

Short sellers are present but not pressing aggressively. Short interest runs at nearly 7% of the free float — elevated enough to matter — and has edged up about 1.4% over the past week. The borrow market, however, is not tight. Availability is ample at roughly 405% of short interest, well above the 52-week floor of 196%, and the cost to borrow has eased 11% on the week to around 0.50%. That lending profile suggests shorts are comfortable holding existing positions into the print but shows no sign of a new wave of conviction building against the stock. The ORTEX short score has also drifted lower over the past two weeks, from around 56 to 54.7, reinforcing that short-side pressure is fading at the margin rather than intensifying.

Insider activity offers a quietly constructive footnote: both the CEO and an EVP made open-market purchases in mid-May near $20, when the stock traded well below current levels. The CFO trimmed a small position in July, but at lower significance — the net 90-day insider flow is mildly positive in dollar terms. Dodge & Cox remains the dominant holder with nearly 14% of shares, and the broader institutional register has seen incremental buying from BlackRock, Fidelity, and T. Rowe Price through the end of June.

Wednesday's print is ultimately a test of whether the product momentum in companion animal health can push through into margin recovery — or whether the debt-servicing drag continues to widen the gap between revenue growth and bottom-line delivery.